Development of a Population Pharmacokinetic Model for the Diroximel Fumarate Metabolites Monomethyl Fumarate and 2-Hydroxyethyl Succinimide Following Oral Administration of Diroximel Fumarate in Healthy Participants and Patients with Multiple Sclerosis-Reference-Cited by-同舟云学术

Development of a Population Pharmacokinetic Model for the Diroximel Fumarate Metabolites Monomethyl Fumarate and 2-Hydroxyethyl Succinimide Following Oral Administration of Diroximel Fumarate in Healthy Participants and Patients with Multiple Sclerosis

Published:2022-01-18 Issue:1 Volume:11 Page:353-371
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Kuchimanchi Mita,Bockbrader Howard,Dolphin Nancy,Epling Daniel,Quinlan Lauren,Chapel Sunny,Penner Natasha

Funder

Biogen

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40120-021-00316-6.pdf

Reference18 articles.

1. Doshi A, Chataway J. Multiple sclerosis, a treatable disease. Clin Med (Lond). 2016;16:s53–9.

2. Biogen: VUMERITY®(diroximel fumarate) delayed-release capsules, for oral use. 2021. https://www.vumerity.com/content/dam/commercial/vumerity/pat/en_us/pdf/vumerity-prescribing-information.pdf. Accessed 18 Nov 2021.

3. Palte MJ, Wehr A, Tawa M, et al. Improving the gastrointestinal tolerability of fumaric acid esters: early findings on gastrointestinal events with diroximel fumarate in patients with relapsing-remitting multiple sclerosis from the phase 3, open-label EVOLVE-MS-1 study. Adv Ther. 2019;36:3154–65.

4. Biogen: TECFIDERA® (dimethyl fumarate) delayed-release capsules, for oral use. 2021. https://www.tecfidera.com/content/dam/commercial/tecfidera/pat/en_us/pdf/full-prescribing-info.pdf. Accessed 18 Nov 2021.

5. Wehr A, Hard M, Yu M, Leigh-Pemberton R, von Moltke L. Relative bioavailability of monomethyl fumarate after administration of ALKS 8700 and dimethyl fumarate in healthy subjects. Neurology. 2018;90:P1.403.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data;Drug Design, Development and Therapy;2022-11